Lipocine director granted options for 2,000 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Lipocine director Michael Grissinger received a grant of 2,000 stock options on August 3, 2026, each for Lipocine common stock at an exercise price of $2.11 per share and expiring on August 3, 2036. The options are subject to vesting: one-third of the shares vest on the one-year anniversary of August 3, 2027, and the remaining two-thirds vest monthly on a prorata basis over the following two years. The transaction was not reported as made under a Rule 10b5-1 trading plan.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 2,000 | $2.11 | $4K |
Footnotes (1)
- F1. Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of August 3, 2027, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorata basis over the following two years.
Key Figures
Key Terms
Stock Option (Right to Buy) financial
vesting financial
Common Stock financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Lipocine (LPCN) director Michael Grissinger report on this Form 4?
How many Lipocine (LPCN) stock options were granted and at what exercise price?
What is the vesting schedule for Michael Grissinger's LPCN stock options?
When do the Lipocine (LPCN) options awarded to Grissinger expire?
Were Michael Grissinger’s Lipocine (LPCN) option grants made under a Rule 10b5-1 plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.